Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer.
暂无分享,去创建一个
[1] R. Muschel,et al. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. , 1998, Cancer research.
[2] F. McCormick,et al. Activators and effectors of ras p21 proteins. , 1994, Current opinion in genetics & development.
[3] R. Coffey,et al. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] Anne J. Ridley,et al. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors , 1992, Cell.
[5] F. McCormick. Ras biology in atomic detail , 1996, Nature Structural Biology.
[6] M. Brown,et al. Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[7] J. Urano,et al. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[8] G. Prendergast,et al. Cell Growth Inhibition by Farnesyltransferase Inhibitors Is Mediated by Gain of Geranylgeranylated RhoB , 1999, Molecular and Cellular Biology.
[9] C. Erlichman,et al. Comparison of potential markers of farnesyltransferase inhibition. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] S. Armstrong,et al. CAAX Geranylgeranyl Transferase Transfers Farnesyl as Efficiently as Geranylgeranyl to RhoB (*) , 1995, The Journal of Biological Chemistry.
[11] C. Der,et al. Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes (*) , 1995, The Journal of Biological Chemistry.
[12] D M Leonard,et al. Ras farnesyltransferase: a new therapeutic target. , 1997, Journal of medicinal chemistry.
[13] R. Kerbel,et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. , 1995, Cancer research.
[14] S. Sebti,et al. Design and structural requirements of potent peptidomimetic inhibitors of p21ras farnesyltransferase. , 1994, The Journal of biological chemistry.
[15] G. Prendergast,et al. Activation of the PI3'K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors. , 1999, Cancer research.
[16] A. Guha,et al. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects , 1999, Oncogene.
[17] S. Moores,et al. Sequence dependence of protein isoprenylation. , 1991, The Journal of biological chemistry.
[18] W. R. Bishop,et al. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. , 2000, Cancer research.
[19] D. Lowy,et al. Function and regulation of ras. , 1993, Annual review of biochemistry.
[20] C. Der,et al. ras Proto-Oncogene Activation in Human Malignancy , 1995 .
[21] N. Rosen,et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[22] M. Barbacid,et al. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. , 1995, Oncogene.
[23] C. Der,et al. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[24] N. Rosen,et al. A Farnesyl-Protein Transferase Inhibitor Induces p21 Expression and G1 Block in p53 Wild Type Tumor Cells* , 1998, The Journal of Biological Chemistry.
[25] C. Bowden,et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] R. Muschel,et al. Radiosensitization and apoptosis , 1998, Oncogene.
[27] C. Marshall. Raf gets it together , 1996, Nature.
[28] C. Der,et al. Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers. , 1996, Oncogene.
[29] R. Weinberg,et al. Isolation of a transforming sequence from a human bladder carcinoma cell line , 1982, Cell.
[30] W. R. Bishop,et al. Novel Tricyclic Inhibitors of Farnesyl Protein Transferase , 1995, The Journal of Biological Chemistry.
[31] Peter J. Parker,et al. The activation of phosphatidylinositol 3-kinase by Ras , 1994, Current Biology.
[32] A. Pawson,et al. Proliferation of human malignant astrocytomas is dependent on Ras activation , 1997, Oncogene.
[33] R. Muschel,et al. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. , 1996, Cancer research.
[34] A. Kral,et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice , 1995, Nature Medicine.
[35] G. Prendergast,et al. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton , 1994, Molecular and cellular biology.
[36] R. Kerbel,et al. Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by mutant c-H-ras oncogene expression , 1995, The Journal of cell biology.
[37] N. Rosen,et al. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. , 1995, Cancer research.
[38] P. Casey,et al. Inhibition of purified p21 ras farnesyl:protein transferase by Cys-AAX tetrapeptides , 1990, Cell.
[39] J. L. Bos,et al. ras oncogenes in human cancer: a review. , 1989, Cancer research.
[40] S. Frisch,et al. Disruption of epithelial cell-matrix interactions induces apoptosis , 1994, The Journal of cell biology.
[41] Sally J. Leevers,et al. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane , 1994, Nature.
[42] London P. Cuatrecasas. GTPases in Biology I , 1993, Handbook of Experimental Pharmacology.
[43] M. Schwartz,et al. The extracellular matrix as a cell survival factor. , 1993, Molecular biology of the cell.
[44] N. Hay,et al. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. , 1997, Genes & development.
[45] C. Lange-Carter,et al. A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf , 1993, Science.
[46] E K Rowinsky,et al. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] G. Prendergast,et al. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. , 1997, Cancer research.
[48] Walter A. Korfmacher,et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. , 1998, Cancer research.
[49] C. Der,et al. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? , 1997, Biochimica et biophysica acta.
[50] J. Goldstein,et al. Polylysine and CVIM Sequences of K-RasB Dictate Specificity of Prenylation and Confer Resistance to Benzodiazepine Peptidomimetic in Vitro(*) , 1995, The Journal of Biological Chemistry.
[51] S. Sebti,et al. GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. , 1997, Cancer research.